This paper reports the separation of two chiral antibacterial agents namely, linezolid and tedizolid using a validated high-performance liquid chromatographic method. In the current work, glycopeptide-based chiral column, CHIROBIOTIC® V2 (5-μm particle size, L × I.D. 25 cm × 4.6 mm) was employed with a mobile phase containing methanol and 0.15% aq. trifluoracetic acid (75:25%, v/v) in isocratic elution approach at flow rate of 1 ml min . The separation condition was customized (in terms of resolution values and retention times) was carried out by changing the content of the mobile phase, column temperature, flow rate, and so on. Results showed that the chromatographic separation was achieved within 15 min and average resolution values were 4.6 and 4.8 for tedizolid and linezolid, respectively. The detection limit values were 14.85 and 14.16 ng ml , respectively, for tedizolid enantiomers. Further, validation of separation parameters was performed by considering the international conference on harmonization guidelines, and ultimately, the mechanism of chiral recognition was also established.

Download full-text PDF

Source
http://dx.doi.org/10.1002/chir.23472DOI Listing

Publication Analysis

Top Keywords

linezolid tedizolid
8
tedizolid validated
8
validated high-performance
8
high-performance liquid
8
liquid chromatographic
8
chromatographic method
8
mobile phase
8
flow rate
8
resolution values
8
enantioseparation linezolid
4

Similar Publications

Penetration of antimicrobial treatments into the cerebrospinal fluid is essential to successfully treat infections of the central nervous system. This penetration is hindered by different barriers, including the blood-brain barrier, which is the most impermeable. However, inflammation may lead to structural alterations of these barriers, modifying their permeability.

View Article and Find Full Text PDF

Study on the Efficacy and Safety of Tedizolid in Japanese Patients.

Antibiotics (Basel)

December 2024

Department of Infectious Diseases, St. Luke's International Hospital, Tokyo 104-8560, Japan.

: Tedizolid (TZD), an oxazolidinone, causes fewer adverse events than linezolid (LZD). However, studies on the long-term efficacy and safety of TZD, particularly in patients with hematological malignancies (HMs), remain limited. This study aimed to evaluate the safety of long-term TZD use in Japanese patients, including those with HM.

View Article and Find Full Text PDF

Clinical efficacy and safety assessment of tedizolid using therapeutic drug monitoring.

J Infect Chemother

December 2024

Department of Infection Prevention and Control, Aichi Medical University Hospital, Nagakute, Aichi, Japan; Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Nagakute, Aichi, Japan. Electronic address:

Thrombocytopenia derived from tedizolid (TZD) has been reported but less frequently than that from linezolid. Only a few reports have investigated the relationship between the efficacy and safety of TZD administration. This study aimed to measure TZD concentration and investigate the relationship between efficacy and safety.

View Article and Find Full Text PDF

Objective: The objective of this study was to investigate the cumulative fraction of response of various dosage regimens of tedizolid phosphate against Staphylococcus aureus and Streptococcus pneumoniae in children, adolescents, and adults.

Methods: Monte Carlo simulations were performed using previously published pharmacokinetic parameters and pharmacodynamic data to evaluate the efficacy of the simulated dosage strategies in terms of area under the concentration-time curve/minimum inhibitory concentration targets of tedizolid.

Results: According to the results of the Monte Carlo simulations, currently approved dosage regimens of tedizolid phosphate were effective in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by methicillin-susceptible S.

View Article and Find Full Text PDF
Article Synopsis
  • Vancomycin is a key antibiotic for treating MRSA infections, but its overuse has led to increased bacterial resistance, prompting this study to find better alternatives.
  • The research analyzed data from 38 trials involving 6,281 patients, measuring clinical success rates and adverse reactions of various antibiotics, including linezolid and combinations of other drugs with vancomycin.
  • Results indicated that linezolid and certain drug combinations outperformed vancomycin in treating MRSA infections, showing higher success rates and lower resistance, while also highlighting the risks of more side effects with some treatments.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!